 |
|
GABITRIL Offers a Low Potential for Drug Interactions1
| No significant interactions observed with the following drugs: |
| Oral contraceptives |
Cimetidine |
| Theophylline |
Warfarin |
| Digoxin |
Triazolam* |
- No known clinically significant effect on steady-state plasma levels of phenytoin, carbamazepine, valproate, phenobarbital,† or primidone†
Effects of other drugs on GABITRIL
- Valproate had no effect on pharmacokinetics, but in vitro, a 40% increase in free tiagabine was observed‡
- Tiagabine clearance is 60% greater in patients receiving carbamazepine, phenytoin, and phenobarbital (primidone)§
- Hepatic enzyme-inducing drugs reduce half-life to 2-5 hours
Postmarketing reports have shown that GABITRIL has been associated with new onset seizures and status epilepticus in
patients without epilepsy. Dose may be an important predisposing factor in the development of seizures, although seizures have
been reported in patients taking daily doses of GABITRIL as low as 4 mg/day. In most cases, patients were using concomitant
medications (antidepressants, antipsychotics, stimulants, narcotics) considered to lower the seizure threshold. Some seizures
have been observed near the time of a dose increase, even after periods of prior stable dosing.
In nonepileptic patients who develop seizures while on GABITRIL treatment, GABITRIL should be discontinued and
patients should be evaluated for an underlying seizure disorder.
As with other anticonvulsants in the treatment of epilepsy, GABITRIL should be withdrawn gradually to minimize the potential of
increased seizure frequency unless safety concerns require a more rapid withdrawal.
|
|
